A cost-benefit analysis of bortezomib, lenalidomide, and bortezomib/lenalidomide combination therapy for newly diagnosed multiple myeloma Meeting Abstract
| Authors: | Fiala, M. A.; Wildes, T. M.; Shah, G. L.; Ghobadi, A.; Schroeder, M. A.; Stockerl-Goldstein, K. E.; Vij, R. |
| Abstract Title: | A cost-benefit analysis of bortezomib, lenalidomide, and bortezomib/lenalidomide combination therapy for newly diagnosed multiple myeloma |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419700308 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.3108.3108 |
| Notes: | Meeting Abstract: 3108 -- Source: Wos |
